Computeruser.com
Latest News

WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board

FREMONT, Calif. Jan. 19, 2011 Arul M. Chinnaiyan

www.oncomine.org

Biomarker expertise is important to WaferGen as the WaferGen SmartChip system, with its 5000+ nano-well format, is designed to provide faster, more cost-effective biomarker identification and validation for multiple samples and patients.

"WaferGen understands what is needed for high-throughput biomarker profiling in order to complement targeted therapies.  I am eager to share my clinical knowledge to help build even better genomic analysis products," said Dr. Chinnaiyan.

Alnoor Shivji

Arul M. Chinnaiyan M.D Michigan Center February 2006 S.P. Hicks University of Michigan

Dr. Chinnaiyan has received numerous awards, including the Paul Marks Prize in Cancer Research and the AACR Outstanding Investigator Award, authored more than 200 publications, holds several U.S. patents and is funded by the National Institutes of Health, the American Cancer Society, and the Department of Defense.  He is a member of the Institute of Medicine of the National Academies of Science and serves on the National Cancer Institute’s Board of Scientific Advisors.

University of Michigan

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries.  The company currently offers the breakthrough SmartChip Real-Time PCR system, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that the SmartChip system is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing.  In addition, the high throughput capabilities of the SmartChip system enable scientists to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

David Gelfand

http://www.wafergen.com

Forward-Looking Statements

This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits to the company and its development of products as a result of Dr. Chinnaiyan’s membership on the company’s Scientific Advisory Board, statements relating to the expected benefits and advantages of the SmartChip service for gene-expression and cancer research, statements relating to the expected benefits and advantages of the SmartChip technology to other applications, and other statements relating to future events are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

December 31, 2009 www.sec.gov

Contact:

WaferGen

510-651-4450

Don Huffman, CFO

[email protected]

Joyce Strand

[email protected]

SOURCE WaferGen Biosystems, Inc.

Leave a comment

seks shop - izolasyon
basic theory test book basic theory test